Unlock instant, AI-driven research and patent intelligence for your innovation.
A kind of dihydromyricetin-berberine hydrochloride pharmaceutical co-crystal and its preparation method
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of berberine hydrochloride and dihydromyricetin, applied in the field of drug crystallization, to achieve the effect of simple and easy preparation method and clear crystal structure
Active Publication Date: 2021-04-27
MINJIANG UNIV
View PDF8 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
There is no public report on the formation of drug-drug co-crystals between dihydromyricetin and berberine hydrochloride
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0031] Suspend and stir 0.356 g of dihydromyricetin (dihydrate) and 0.407 g of berberine hydrochloride (dihydrate) in 20 mL of absolute ethanol for 24 hours, filter with suction, wash the resulting precipitate with absolute ethanol, and dry in the air; The obtained powder is recrystallized in absolute ethanol to obtain dihydromyricetin-berberine hydrochloride eutectic powder.
[0032] figure 1 It is the XRD figure of the dihydromyricetin-berberine hydrochloride cocrystal prepared in the present embodiment. Depend on figure 1 It can be seen that the prepared crystals are represented by diffraction angle 2θ° ± 0.1 as: 7.4°, 8.2°, 10.2°, 11.0,° 12.6°, 13.9°, 14.5°, 14.8°, 15.8°, 16.5°, 17.2°, 17.5°, 18.3°, 19.0°, 19.4°, 19.7°, 20.0°,20.4°, 20.7°, 21.2°, 22.2°, 23.2°, 24.3°, 25.2°, 26.0°, 26.4°, 27.1°, 27.4° , 27.6 °, 29.1 °, 29.7 °, 30.0 °, 30.8 °, 31.5 °, 32.6 ° have characteristic diffraction peaks.
[0033] figure 2 It is the hydrogen bonding situation between dihydrom...
Embodiment 2
[0037] Mix 0.356 g of dihydromyricetin (dihydrate) and 0.407 g of berberine hydrochloride (dihydrate) in a grindingjar, add 0.2 mL of absolute ethanol dropwise to moisten, and grind in a ball mill for 20 minutes to obtain dihydromyricetin Myricetin-berberine hydrochloride eutectic powder.
Embodiment 3
[0039] Dissolve 0.356 g of dihydromyricetin (dihydrate) and 0.407 g of berberine hydrochloride (dihydrate) in 100 mL of absolute ethanol under heating and stirring conditions, continue to stir after cooling, filter, and stand still to volatilize to obtain di Hydromyricetin-berberine hydrochloride eutectic crystal.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a drug co-crystal of dihydromyricetin-berberinehydrochloride, which belongs to the technical field of drugcrystallization. The present invention combines dihydromyricetin and berberinehydrochloride through intermolecular hydrogen bonding to form the dihydromyricetin-berberinehydrochloridedrug eutectic. The preparation method of the invention is simple and easy, and the cost is low. The prepared dihydromyricetin-berberine hydrochloride drug eutectic structure is clear, without hygroscopicity, and the dissolution rate of dihydromyricetin and berberine hydrochloride in water is similar, and can be dissolved simultaneously, showing a synergistically enhanced effect on specific tumor cells. inhibition.
Description
technical field [0001] The invention belongs to the technical field of medicinecrystallization, and in particular relates to a dihydromyricetin-berberine hydrochloridemedicine co-crystal and a preparation method thereof. Background technique [0002] Drug co-crystals can be formed by combining pharmaceutically active molecules with other physiologically safe small organic molecules through supramolecular interactions. On the premise of not destroying the molecular structure of the drug, the physicochemical properties and druggability of the active drug molecule can be improved by co-crystal formation. Drug-drug co-crystals formed by combining two known pharmaceutically active molecules are expected to exhibit therapeutic effects superior to those of a single drug. After two drug molecules with synergistic therapeutic effects are combined, the respective solubility properties may achieve an optimal balance, which is conducive to maximizing the therapeutic effect. The uniq...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More